(±)-18-MC competitively inhibits α9α10 nAChRs with potencies higher than that at α3β4 and α4β2 nAChRs and directly blocks CaV2.2.
(±)-18-MC competitively inhibits α9α10 nicotinic acetylcholine receptors (nAChRs) with potencies higher than those at α3β4 and α4β2 nAChRs, and directly blocks CaV2.2 channels.